The global healthcare landscape is undergoing a profound transformation, driven by the rise of precision medicine. This new paradigm, which tailors medical treatment to the individual characteristics of each patient, relies heavily on advanced molecular imaging and targeted therapies. At the forefront of this revolution is the field of nuclear medicine, particularly the integrated diagnostic and therapeutic approach known as theranostics. By using specialized radioactive drugs called radiopharmaceuticals, clinicians can now visualize and treat diseases like cancer and heart disease at the molecular level with unprecedented accuracy. However, a significant portion of the world, most notably Latin America, is being left behind due to a critical infrastructure gap. The region's healthcare systems are caught in a paradox: they possess advanced imaging scanners but lack a reliable and affordable supply of the essential radiopharmaceuticals required to operate them, in addition to facing fragmented clinical research environments and a shortage of trained personnel.74 This scarcity often stems from an outdated, fragile global supply chain dependent on a handful of aging nuclear reactors located overseas, a model fundamentally incompatible with the short-lived nature of these vital medical isotopes.
This report provides an in-depth analysis of Synapse Latam, a specialized medical technology company formed to solve this critical problem. It must be stated unequivocally that Synapse Latam is a strategic joint venture between the clinical research experts at bioaccess® and the radiopharmaceutical pioneers at Nucleotron MIT.74 It is in no way affiliated with the financial technology (fintech) firm Synapse Financial Technologies, which recently filed for bankruptcy, nor is it related to other entities in product engineering or insurance that share the "Synapse" name.1
Synapse Latam operates as a global Management Services Organization (MSO), offering a comprehensive solution that empowers hospitals and imaging centers to build and expand their theranostics and clinical research capabilities.74 This is not the offering of a conventional equipment vendor but the deployment of a complete, proven U.S. operational model, using the success of the American molecular imaging leader CIRA Health as a blueprint.74 The company’s core mission is to enable Latin American healthcare systems to participate in and lead the burgeoning field of theranostics through a range of services, including theranostic program development, clinical research administration, and radiopharmaceutical strategy consulting.74
While on-site isotope production is a key challenge, Synapse Latam’s approach is scalable and focuses on clinical enablement first, leveraging existing infrastructure where possible.74 For partners where radiopharmaceutical access is limited or cost-prohibitive, the company provides a turnkey solution centered on exclusive regional access to the
IONETIX ION-12SC, a revolutionary, FDA-cleared superconducting cyclotron that dramatically lowers the cost and complexity of on-site production.74
By integrating cutting-edge technology options with end-to-end program management—from financial modeling and regulatory navigation to operational staffing and clinical trial integration—Synapse Latam de-risks the entire process for its partners.74 The company's business model, which derives revenue from MSO service contracts, implementation fees, and consulting, transforms theranostics from a prohibitive cost center into a profitable engine for clinical and economic leadership.74 This model is validated through a flagship partnership with the prestigious Hospital Internacional de Colombia (HIC), a member of the Mayo Clinic Care Network.6
The long-term vision of Synapse Latam extends beyond individual institutions. The company is actively building a decentralized, resilient, and collaborative isotope manufacturing and clinical research grid across Latin America.6 This network will not only ensure a secure supply of radiopharmaceuticals for the continent but will also establish the region as a global hub for advanced clinical research.74 This report will demonstrate that Synapse Latam offers a meticulously engineered service model to address one of Latin American healthcare's most pressing challenges, presenting a unique and compelling opportunity for healthcare providers, investors, and governments to lead the next wave of medical innovation.
The practice of medicine is shifting from a one-size-fits-all approach to one of remarkable precision. In fields like oncology and cardiology, the ability to diagnose and treat disease is no longer limited to anatomical observation but has advanced to the molecular level. This evolution is powered by the field of Nuclear Medicine, a medical specialty that uses small, safe amounts of radioactive materials, or radiopharmaceuticals, to see how the body is functioning and to treat disease.7 The pinnacle of this approach is
Theranostics, a term derived from the fusion of "therapy" and "diagnostics." This cutting-edge discipline uses a single integrated platform to first find cancer cells anywhere in the body and then deliver targeted radiation to destroy them, embodying the principle of "seeing what you treat, and treating what you see".10
This leap forward in medical capability offers immense promise. Early and accurate diagnosis, personalized treatment plans, and the potential for more effective therapies with fewer side effects are fundamentally changing patient outcomes worldwide.13 Yet, for much of Latin America, this promise remains just out of reach. The region is caught in an "infrastructure-capability paradox".6 Hospitals and clinics have invested in the advanced scanners needed for modern imaging, but they are critically constrained by a lack of access to the radiopharmaceuticals that are the very fuel for these machines.74 The result is underutilized capital equipment, compromised patient scheduling, and missed opportunities to participate in the global advancement of medicine.6
This report introduces Synapse Latam, a company created specifically to resolve this paradox. It is crucial to establish a clear and unambiguous identity for this entity from the outset, as the name "Synapse" is used by several unrelated organizations, creating significant potential for confusion. One such company, Synapse Financial Technologies, a U.S.-based fintech provider with operations in Latin America, recently underwent a high-profile bankruptcy, leading to frozen customer accounts and negative press coverage.4 Further searches reveal Synapse.com, a product engineering firm owned by Capgemini 1, and Synapsellc.com, a specialty insurance broker.2 The inaccessibility of Synapse Latam's own website 20 creates an information vacuum that is easily filled by these other, irrelevant entities.
To be perfectly clear: Synapse Latam is a highly specialized medical technology company, formed as a strategic joint venture between the clinical research organization bioaccess® and the radiopharmaceutical technology pioneers Nucleotron MIT.74 Its mission is focused entirely on the healthcare sector, with no connection whatsoever to banking, fintech, consumer product design, or insurance. Synapse Latam operates as a
global Management Services Organization (MSO), a strategic implementation partner that delivers a complete, end-to-end operational model designed to empower Latin American healthcare institutions to build world-class theranostics programs, close the region's critical infrastructure gap, and usher in a new era of medical leadership.74
To grasp the magnitude of the opportunity that Synapse Latam unlocks, one must first understand the fundamental science that drives modern nuclear medicine. Unlike anatomical imaging modalities like X-rays or standard Computed Tomography (CT) scans, which provide a static picture of the body's structures, nuclear medicine reveals the body's function in real time.
At the heart of nuclear medicine are radiopharmaceuticals, a unique class of drugs containing a small, safe amount of a radioactive substance known as a radioisotope.21 These drugs are engineered with remarkable precision. They consist of two main components: a "targeting molecule" that is biologically programmed to seek out and bind to specific cells or receptors in the body (such as those on the surface of a tumor), and a "radioactive tag" (the radioisotope) that is attached to it.22 This structure acts like a biological GPS tracker, navigating through the bloodstream to its precise destination.
For diagnostic purposes, the radioactive tag is chosen for its ability to emit signals—specifically, subatomic particles called positrons—that can be detected outside the body. This is the basis of Positron Emission Tomography (PET) scanning.26 When a patient is injected with a diagnostic radiopharmaceutical, it travels to its target. For example, a common radiopharmaceutical called Fluorodeoxyglucose (FDG) is a radioactive form of sugar.28 Since cancer cells are highly metabolic and consume more sugar than normal cells, the FDG accumulates in tumors.26
The patient then lies inside a PET scanner, a machine that detects the signals emitted by the radiopharmaceutical. A powerful computer processes these signals to create a detailed, three-dimensional map showing where the drug has accumulated.27 This provides a functional image of the body's metabolic activity. The difference between a CT scan and a PET scan can be understood with an analogy: a CT scan provides a detailed road map of a city, showing every street and building (anatomy). A PET scan, however, shows the traffic on those roads, highlighting the areas with the most activity (function).30 These "hot spots" on a PET scan can reveal the presence, size, and spread of cancer with a level of sensitivity that other imaging techniques cannot match.28
The next evolution of this technology is theranostics, which seamlessly combines diagnosis with therapy.11 The process begins with a diagnostic PET scan to confirm that a patient's tumor has the specific molecular target that the drug is designed to find. If the target is present, the patient is eligible for treatment. The therapeutic step uses the very same "GPS tracker" (the targeting molecule), but the diagnostic radioactive tag is swapped for a more powerful therapeutic one.11
This therapeutic radioisotope emits a different type of radiation (such as alpha or beta particles) that is potent enough to damage and destroy the cells it attaches to.11 It functions as a "molecular smart bomb," delivering a highly targeted dose of radiation directly to cancer cells while minimizing damage to surrounding healthy tissue.14 This approach is particularly effective for treating metastatic cancers that have spread throughout the body, where traditional external beam radiation would be impractical or too toxic.25
Despite the immense clinical value of these technologies, their adoption in Latin America has been severely hampered by a deeply flawed global supply chain. The region is almost entirely dependent on imported radioisotopes, a model that is both logistically challenging and economically unsustainable.16
The world's supply of key medical radioisotopes, particularly Molybdenum-99 ($^{99}Mo),whichdecaysintothemostwidelyuseddiagnosticisotope,Technetium−99m(^{99m}$Tc), is concentrated in a small number of aging nuclear research reactors.35 These facilities are located primarily in Europe, North America, and South Africa, with only a handful of countries in Latin America—such as Argentina, Brazil, and Mexico—having any, albeit limited, production capability.33 This centralized production model creates a precarious dependency for the rest of the world. The scheduled or unscheduled shutdown of just one of these decades-old reactors can trigger global shortages, disrupting patient care on a massive scale.36
The fundamental challenge of radiopharmaceutical supply is rooted in physics. Radioactive isotopes are inherently unstable and decay over time, a process measured by their "half-life"—the time it takes for half of the radioactive atoms in a sample to decay. For many of the most important PET isotopes, this half-life is extremely short. Fluorine-18 ($^{18}F),theworkhorseofPETimaging,hasahalf−lifeofjustunder110minutes.[38,39]Nitrogen−13(^{13}$N), the preferred agent for cardiac PET imaging, has a half-life of less than 10 minutes.40
This rapid decay makes long-distance transportation a race against time. A dose produced in Europe or Canada loses a significant portion of its potency by the time it clears customs and reaches a hospital in South America. This not only drives up the cost per effective dose but also creates enormous logistical hurdles, requiring just-in-time delivery through a complex and often unreliable cold chain.41
The fragility of this system has been repeatedly exposed. The COVID-19 pandemic, for example, brought global air freight to a near standstill, severely disrupting the distribution of medical isotopes.42 Even as reactors continued to produce, the inability to transport the product led to canceled production runs and forced hospitals to reschedule or cancel critical patient procedures.43 This reliance on a few distant producers and a fragile transportation network makes the supply chain for Latin America chronically unreliable, expensive, and ill-suited to meet the growing demand for nuclear medicine.45
The consequences of this broken supply chain are profound, impacting both individual patients and the healthcare institutions that serve them.
For patients in Latin America, the scarcity of radiopharmaceuticals translates directly into a lower standard of care. The continent's growing and aging population is facing a rising tide of cancer and cardiovascular disease, the very conditions for which nuclear medicine is most effective.16 Yet, access to these life-saving diagnostic and therapeutic procedures is often uneven and limited, particularly outside of major urban centers.16 Patients may face long waiting lists for scans, leading to delayed diagnoses that can worsen prognoses for aggressive diseases. They may be denied access to innovative theranostic treatments that are becoming the standard of care elsewhere. In many cases, patients who can afford it must undertake expensive and arduous travel to other cities or even other countries to receive the care they need, while the majority simply go without.16
For hospitals and imaging centers, the situation is equally dire. They find themselves in an "infrastructure-capability paradox".6 An institution might invest millions of dollars in a state-of-the-art PET/CT scanner, only to see it sit idle for significant periods due to the unreliable and costly supply of imported radiopharmaceuticals. This underutilization makes it impossible to generate a return on a major capital investment.6
This dynamic creates a vicious economic cycle. Because the supply is unpredictable and expensive, hospitals cannot build a reliable, high-volume nuclear medicine service. Without the patient volume, they cannot achieve economies of scale or justify the investment in the specialized staff and facilities needed to run a world-class department. This lack of established, high-quality infrastructure, in turn, makes them unattractive partners for global pharmaceutical companies seeking sites for lucrative clinical trials of new radiopharmaceuticals. Deprived of the revenue, prestige, and clinical expertise that come from participating in cutting-edge research, these institutions remain stuck in a cycle of import dependency and constrained capability. The inability to offer the highest standard of care hinders their ability to attract top medical talent and be recognized as leaders in their field. Synapse Latam's model is designed to break this very cycle.
To solve the multifaceted problem of radiopharmaceutical scarcity and fragmented research capabilities, a simple equipment sale is insufficient. The challenge requires a holistic solution that addresses technology, infrastructure, regulation, operations, and finance simultaneously. This is the foundation of the Synapse Latam model: a comprehensive Management Services Organization (MSO) that deploys a proven U.S. operational model to guide healthcare institutions toward clinical and research leadership.74
The traditional approach to establishing advanced medical services places an enormous burden on the healthcare institution. Synapse Latam introduces a fundamentally different paradigm focused on clinical enablement and strategic partnership.74
In the conventional model, a hospital that wants to build an on-site production facility purchases a cyclotron from a manufacturer as a standalone piece of equipment.6 From that point forward, the hospital bears the full weight of a daunting series of tasks. It must independently manage the design and construction of a heavily shielded, multi-million-dollar vault; navigate labyrinthine regulatory approvals; recruit and train highly specialized personnel; and develop complex operating procedures to ensure GMP compliance.6 This approach places all the technical, regulatory, operational, and commercial risk squarely on the shoulders of the buyer.6
Synapse Latam operates not as a vendor, but as a single, accountable strategic partner that manages the entire lifecycle of program development.74 This offering is best understood as the deployment of a complete, proven U.S. operational model, using the molecular imaging leader
CIRA Health as a blueprint for success in theranostic trial integration and PET network management.74 The core principle is
clinical enablement first, focusing on the rapid launch of clinical services and research participation, often using a partner's existing infrastructure.74 This turnkey MSO approach is designed to de-risk the entire endeavor for the partner institution, eliminating the "coordination friction and blame-shifting" that can derail complex projects and ensuring a streamlined path to operation.6
The power of the Synapse Latam solution lies in its integrated nature, combining comprehensive services with deep regional expertise and access to cutting-edge technology when needed.74 This creates a self-reinforcing ecosystem that ensures success at every stage. The MSO model is built on several core service lines 74:
This comprehensive service offering is made possible by the unique structure of Synapse Latam as a strategic joint venture. This partnership combines the distinct, complementary strengths of two industry leaders 74:
By providing a fully integrated ecosystem of services, expertise, and technology options, Synapse Latam offers its partners a single, accountable entity to ensure success. This transforms the decision from a high-risk capital expenditure into a strategic, de-risked investment in a complete, revenue-generating clinical program.6
While Synapse Latam’s MSO model prioritizes clinical enablement with existing infrastructure, a critical component of its radiopharmaceutical strategy for certain partners is the option for on-site isotope production.74 For institutions where isotope access is limited or cost-prohibitive, Synapse Latam provides exclusive regional access to the IONETIX ION-12SC cyclotron. This technology is not just an incidental choice; it is a revolutionary system whose unique design directly addresses the primary cost and complexity drivers that have historically made on-site production prohibitive.74
In simple terms, a cyclotron is a type of particle accelerator, a machine designed to produce the short-lived radioactive isotopes required for PET imaging and other nuclear medicine applications.50 The process can be understood through an analogy: think of it as a highly sophisticated, super-powered slingshot.
Inside a vacuum chamber, the cyclotron uses a combination of powerful magnets and a rapidly alternating electric field to take stable, charged particles (typically protons) and accelerate them along a spiral path to incredibly high speeds.53 Once these particles reach the desired energy level, they are directed to slam into a specific target material. This high-energy collision causes a nuclear reaction, transforming the stable atoms of the target material into new, unstable (radioactive) atoms—the medical isotopes.52 For example, by bombarding a target of enriched water (
H218O) with protons, the cyclotron creates the PET isotope Fluorine-18 ($^{18}$F).56
Having a cyclotron on-site is the definitive solution to the "tyranny of the half-life." It allows a hospital to produce these essential, short-lived isotopes on demand, precisely when they are needed for patient scans, completely eliminating the reliance on the fragile and inefficient long-distance supply chain.38
While many companies produce medical cyclotrons, the IONETIX ION-12SC, the heart of the Synapse Latam on-site production solution, represents a significant leap forward in the technology. It is not just another cyclotron; it is a revolutionary system whose design features directly translate into major cost and operational advantages for the healthcare institution.6
The disruptive nature of this technology is precisely what makes it a powerful component of the Synapse Latam MSO offering. The high capital and operational expenditures associated with traditional cyclotrons from major manufacturers like GE Healthcare, IBA, or Sumitomo Heavy Industries make achieving a rapid return on investment extremely challenging.47 The ION-12SC's ability to slash these costs is the key that unlocks the financial feasibility of on-site production for many institutions that would otherwise be excluded.
For a business-oriented audience, translating technical specifications into clear financial and operational metrics is paramount. The following table distills complex engineering data into a simple, powerful comparison, visually demonstrating why the ION-12SC is a disruptive technology by quantifying its benefits in terms of cost, space, and operational simplicity.
Synapse Latam's offering transcends technology or service sales; it is a comprehensive business solution designed to establish its partners as regional leaders in both clinical care and financial performance.74 The business case is built upon a flexible MSO service model, validated by a flagship partnership with a world-class institution, and underpinned by unparalleled regulatory expertise that accelerates time-to-market.74
The traditional model of importing radiopharmaceuticals or attempting a fragmented facility build-out treats nuclear medicine as a high-cost, low-margin service. The Synapse Latam MSO model inverts this dynamic, transforming the theranostics program into a strategic asset and a potential profit center.74 Revenue is derived from MSO service contracts, implementation fees, research administration, and consulting engagements, which are justified by the powerful outcomes enabled for the partner institution.74 These outcomes include:
The theoretical power of this model is being demonstrated in practice through a flagship partnership with the Hospital Internacional de Colombia (HIC) in Bucaramanga.6 This collaboration serves as a critical proof point and a blueprint for future partners.
HIC is not an ordinary hospital. It is a leading healthcare institution in Colombia, consistently ranked as one of the best hospitals in all of Latin America. It is recognized for its advanced specialty services in oncology, cardiology, and neurology, and for its commitment to innovation and quality, holding certifications like HIMSS EMRAM 7 for its advanced use of technology.68
At HIC, Synapse Latam is deploying its full turnkey solution, establishing a state-of-the-art radiopharmacy centered on the ION-12SC cyclotron. This will provide HIC with the on-site production capabilities needed to support and expand its world-class oncology and cardiology programs, enabling the full utilization of its advanced imaging equipment and providing its physicians with the tools they need to deliver the highest standard of care.6
The most powerful endorsement of the quality and operational excellence that the Synapse Latam model fosters comes from an independent, globally respected third party. HIC is the first hospital in Colombia to be accepted into the prestigious Mayo Clinic Care Network. This is not a symbolic affiliation; acceptance into this network requires a rigorous evaluation by Mayo Clinic of a hospital's clinical practices, quality standards, and patient safety protocols.6
This alliance validates that HIC operates at a world-class level, a standard that the Synapse Latam infrastructure helps to establish and maintain. This partnership grants HIC's physicians direct access to Mayo Clinic's vast knowledge base and expert consultations, further enhancing their clinical programs. For Synapse Latam and its future partners, the HIC-Mayo Clinic alliance creates a powerful "halo effect." It demonstrates that adopting the Synapse Latam model can elevate an institution to a level of operational excellence recognized by the world's leading medical centers, thereby attracting further collaborations, top-tier clinical trials, and the best medical talent in the region.6
One of the most significant and often underestimated barriers to entry for any new medical technology in Latin America is the complex and varied regulatory landscape. Each country has its own health authority with unique requirements, processes, and timelines. Successfully navigating this labyrinth is critical to getting a facility operational.
This is where the expertise of Synapse Latam's joint venture partner, bioaccess®, becomes a core component of the value proposition. The team possesses deep, established relationships with key personnel and a granular understanding of the specific documentation and procedural requirements for the region's primary regulatory bodies, including 6:
This specialized expertise is not a minor convenience; it is a major strategic accelerator. Synapse Latam projects that its deep regulatory know-how can shorten the time from project inception to operational launch by as much as 40% compared to traditional pathways.6 For a partner institution, this translates into millions of dollars in saved costs and, more importantly, a faster path to treating patients and generating revenue.
The ambition of Synapse Latam extends far beyond the success of any single institution. The company's long-term vision is to fundamentally re-engineer the theranostics landscape of an entire continent, moving from a model of scarcity and dependence to one of resilience, collaboration, and self-sufficiency.74
The ultimate goal is not simply to install a series of isolated cyclotrons or enable individual programs. Instead, Synapse Latam is strategically building a distributed, resilient, and collaborative theranostics and clinical research grid across Latin America.74 This is a network of interconnected centers, all operating under the same world-class protocols and leveraging standardized technologies and processes where appropriate.
The roadmap for this vision is already in motion. It begins with the flagship site at the Hospital Internacional de Colombia (HIC) serving as the foundational node. From there, the company has a clear target to expand the network to a total of seven sites across the region by the year 2027.6 This deliberate, phased expansion is designed to create a critical mass of production and research capability that can serve the entire continent.
The establishment of this regional grid will have profound, transformative implications for healthcare, research, and economic development in Latin America. It represents a shift from a reactive to a proactive stance, creating a system that is inherently more robust and innovative.
A decentralized network of production sites provides a level of supply security that is currently unimaginable in the region. In the current import-dependent model, the shutdown of a single overseas reactor can cut off supply for thousands of patients. In the future network envisioned by Synapse Latam, if one production site in the grid is temporarily down for maintenance, other nodes in the network can step in to supply its local area. This creates redundancy and resilience, ensuring that patient care is not disrupted and that the multi-million-dollar investments in PET scanners across the region can be consistently utilized.6
The creation of this network does more than just solve a supply problem; it actively creates a new market. Currently, the market for large-scale, multi-center clinical trials for new radiopharmaceuticals in Latin America is severely underdeveloped due to the lack of standardized, reliable infrastructure.74 Global pharmaceutical companies are hesitant to invest in complex trials across a region where each site has different equipment, different operating procedures, and an unreliable supply of isotopes.
The Synapse Latam network directly solves this problem. By creating a grid of sites all operating under the same high-quality, GMP-compliant standards, and leveraging standardized technology where needed, Synapse Latam is building the very platform required for this market to flourish.74 It establishes a standardized, attractive, and reliable ecosystem for conducting cutting-edge research. This has the potential to transform Latin America from a clinical trial backwater into a premier, go-to destination for radiopharmaceutical research and development, bringing investment, expertise, and innovation to the region.6
This strategy creates a powerful network effect. As more hospitals join the Synapse Latam network, the platform becomes exponentially more valuable to international pharmaceutical sponsors looking to conduct large-scale trials. This, in turn, drives more revenue, prestige, and research opportunities back to the partner hospitals, creating a self-reinforcing cycle of growth and innovation. In this scenario, Synapse Latam is not just a service provider; it is a market maker, building the "interstate highway system" for the next generation of nuclear medicine in the Americas.
Ultimately, the grand vision of Synapse Latam is to democratize access to the most advanced medical care for millions of people across the continent.6 By breaking the cycle of dependency on foreign supply and fostering local, self-sufficient theranostics programs, this model ensures that a patient's access to life-saving diagnostics and therapies is no longer determined by their proximity to an international airport or the stability of global logistics. It empowers local institutions to become centers of excellence, fostering regional innovation and securing a prominent place for Latin America in the global advancement of medical research.74
The landscape of modern medicine is being redrawn by the power of nuclear medicine and theranostics, yet Latin America has been largely excluded from this revolution by a fragile, outdated, and economically unsustainable supply chain for essential radiopharmaceuticals.6 This has created a critical gap between the region's clinical capabilities and its potential, leading to underutilized equipment, delayed patient diagnoses, and missed opportunities for medical and economic leadership.6
Synapse Latam has emerged with a definitive and comprehensive solution to this pressing challenge. Operating as a Management Services Organization (MSO), the company moves beyond the role of a simple equipment vendor to deliver a fully integrated ecosystem that empowers healthcare institutions to build world-class theranostics and clinical research programs.74 This is accomplished through a strategic synthesis of three core elements:
This model is not theoretical. It is being actively validated through a flagship partnership with the Hospital Internacional de Colombia, an institution whose own world-class standards are affirmed by its membership in the Mayo Clinic Care Network.6 The long-term vision is even more ambitious: to construct a resilient, decentralized grid of theranostics centers that will not only secure the continent's supply of these life-saving drugs but will also create a new, vibrant market for pan-regional clinical research, positioning Latin America as a global leader in medical innovation.74
For hospital administrators, healthcare investors, and public health officials across the Americas, the message is clear. The era of dependency and scarcity is over. A de-risked, profitable, and strategically sound path to leadership in precision medicine is now available. Engaging with Synapse Latam represents a unique opportunity to not only elevate the standard of care for millions of patients but also to secure a lasting position at the forefront of the next generation of healthcare. The first step is to initiate a dialogue to explore how this proven MSO model can be deployed to meet the specific needs of your institution and your nation.
Q: What is Synapse Latam?
A: Synapse Latam is a specialized medical technology company formed as a strategic joint venture between bioaccess® and Nucleotron MIT. It operates as a Management Services Organization (MSO) to empower Latin American healthcare institutions in building and expanding their theranostics and clinical research capabilities.
Q: How is Synapse Latam different from Synapse Financial Technologies?
A: It is crucial to understand that Synapse Latam is in no way affiliated with the financial technology (fintech) firm Synapse Financial Technologies, nor is it related to other entities in product engineering or insurance that share the "Synapse" name. Synapse Latam is entirely focused on the healthcare sector.
Q: What problem does Synapse Latam address in Latin America?
A: Latin America faces a critical infrastructure gap in healthcare, particularly in nuclear medicine. Hospitals often have advanced imaging scanners but lack a reliable and affordable supply of essential radiopharmaceuticals, leading to underutilized equipment and limited access to precision medicine. Synapse Latam solves this by providing comprehensive solutions for radiopharmaceutical access and theranostics program development.
Q: What is the IONETIX ION-12SC cyclotron, and why is it important to Synapse Latam's solution?
A: The IONETIX ION-12SC is a revolutionary, FDA-cleared superconducting cyclotron that dramatically lowers the cost and complexity of on-site radiopharmaceutical production. While Synapse Latam's MSO model prioritizes clinical enablement with existing infrastructure, for partners where radiopharmaceutical access is limited or cost-prohibitive, the ION-12SC provides a turnkey solution for reliable, on-demand isotope production.
Q: How does Synapse Latam's MSO model generate revenue?
A: Synapse Latam's business model derives revenue from MSO service contracts, implementation fees, and consulting. By enabling on-site radiopharmaceutical production and high-value clinical research, the model transforms theranostics from a cost center into a profitable engine for clinical and economic leadership for its partners.
Q: What is the significance of the partnership with Hospital Internacional de Colombia (HIC)?
A: The flagship partnership with HIC, a member of the Mayo Clinic Care Network, serves as a critical proof point and blueprint for future partners. It demonstrates that the Synapse Latam model can elevate an institution to world-class operational excellence, attracting top medical talent, clinical trials, and further collaborations.
Q: How does Synapse Latam address regulatory challenges in Latin America?
A: Synapse Latam leverages the deep regulatory expertise of its joint venture partner, bioaccess®. This expertise, combined with established relationships with key regional health authorities like INVIMA (Colombia), ANVISA (Brazil), and COFEPRIS (Mexico), significantly shortens the time from project inception to operational launch by as much as 40%.
Q: What is Synapse Latam's long-term vision for Latin America?
A: The long-term vision is to build a decentralized, resilient, and collaborative isotope manufacturing and clinical research grid across Latin America. This network will ensure a secure supply of radiopharmaceuticals and establish the region as a global hub for advanced clinical research, democratizing access to modern medicine for millions.